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Abstract
Purpose—Vancomycin is the standard antibiotic for treatment of methicillin-resistant 
Staphylococcus aureus (MRSA) infections. While daptomycin is approved for MRSA bacteremia, 
its effectiveness in osteoarticular infections (OAI) has not been established.
Methods—1:2 nested case-control study of adult patients with MRSA OAI admitted to an 
academic center from 2005–2010. Clinical outcomes and drug toxicity in patients treated with 
daptomycin vs. vancomycin were compared.
Results—20 patients with MRSA OAI treated with daptomycin were matched to 40 patients 
treated with vancomycin. Median age was 52 years (range, 25–90), and 40 (67%) were male. Most 
patients had osteomyelitis (82%), predominantly from a contiguous source (87%). Forty percent 
were diabetics. Diabetic patients were more likely to receive vancomycin than daptomycin [20 
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(50%) vs. 4 (20%); p=0.03]. Vancomycin was more often combined with other antibiotics than 
daptomycin [22 (55%) vs. 5 (25%); p=0.03]. Median total antibiotic treatment duration was 48 
(daptomycin) vs. 46 days (vancomycin) (p=0.5). 90% of daptomycin-treated patients had 
previously received vancomycin for a median 14.5 days (range, 2–36). Clinical success rates were 
similar between daptomycin and vancomycin at 3 months [15 (75%) vs. 27 (68%); p=0.8] and 6 
months [14 (70%) vs. 23 (58%); p=0.5], even after propensity score-based adjustment for 
antibiotic assignment. Frequency of adverse events was similar between treatment groups [1 (5%) 
vs. 7 (18%); p=0.2].
Conclusions—Daptomycin and vancomycin achieved similar rates of clinical success and drug 
tolerability. Daptomycin is a reasonable alternative for treating MRSA OAIs, particularly in 
patients where therapy with vancomycin has not been well-tolerated.
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Background
Staphylococcus aureus is the most common cause of osteoarticular infections (OAIs) [1]. 
Appropriate antibiotic therapy is tailored to the antibiotic resistance profile of the individual 
S. aureus isolate. Methicillin-resistant S. aureus (MRSA) is typically treated with 
vancomycin, a glycopeptide antibiotic. Vancomycin, however, has the potential to cause 
significant nephrotoxicity [2]. The emergence of vancomycin-intermediate S. aureus (VISA) 
has further limited its use in many settings [3].
Daptomycin is the first of a new class of antibiotics, the cyclic lipopeptides, and has a 
mechanism of action unlike any other currently marketed antibiotic [4]. It is bactericidal and 
active against otherwise drug-resistant Gram-positive bacteria. Daptomycin is also well-
tolerated and convenient to administer, making it a desirable option for outpatient parenteral 
antibiotic therapy [5]. It is currently approved in the United States for the treatment of skin 
and soft tissue infections, bloodstream infections, and right-sided endocarditis. Since its 
initial introduction in 2003, daptomycin has been increasingly used in the management of 
OAIs [6]. Common reasons for using daptomycin in MRSA OAIs include intolerance to or 
failure of the standard antibiotic treatment. Vancomycin failures have been attributed to poor 
bone penetration, increasing minimum inhibitory concentrations (MIC), and difficult-to-
titrate dosing requiring frequent monitoring of drug levels [7].
A number of case series and analyses of registries have demonstrated that daptomycin can 
achieve high cure rates in osteoarticular infections [6, 8–10]. Gonzalez-Ruiz and colleagues 
reported findings from 64 cases of osteomyelitis seen in Europe where success was achieved 
in 80% [11]. Few studies have compared daptomycin vs. vancomycin for treatment of OAIs. 
Moenster et al. published a case-control study of 51 patients with osteomyelitis but did not 
exclusively focus on MRSA infections; patients treated with daptomycin had significantly 
fewer recurrent infections six months after completing intravenous antibiotics [12]. Lalani et 
al. performed a post hoc subanalysis of OAIs identified in a randomized controlled trial of 
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patients with staphylococcal bloodstream infection and right-heart endocarditis, and found 
higher success rates in the daptomycin group [13].
Our objective was to analyze data from a retrospective cohort of OAIs and compare patient 
characteristics, clinical manifestations, and outcomes of MRSA OAIs treated with either 
daptomycin or vancomycin.
Methods
Study design, setting, and inclusion/exclusion criteria
This was a 1:2 nested case-control study performed at Barnes-Jewish Hospital (BJH), a 
1250-bed tertiary care hospital. We included adult patients admitted to BJH between August 
1, 2005 and July 31, 2010 who were diagnosed with methicillin-resistant Staphylococcus 
aureus (MRSA) osteomyelitis or septic arthritis per tissue or fluid culture (with 
documentation of the infection in their medical records). Cases and controls were selected 
based on antibiotic assignment. All patients with MRSA osteomyelitis or septic arthritis 
treated with daptomycin during the specified time frame were included as cases, regardless 
of the duration of treatment. We matched controls treated with vancomycin to cases by 
month and year of hospital admission. No further matching was performed in order to allow 
analysis of potential factors influencing antibiotic selection. We excluded patients with: 1) 
polymicrobial infections, 2) persistent bacteremia (>72 hours), and 3) concurrent 
endocarditis. Eligible patients were identified using the hospital’s outpatient intravenous 
antibiotic registry. The diagnosis of MRSA osteomyelitis or septic arthritis was confirmed 
by microbiology records for all patients in the study.
Data collection, outcomes, and statistical analysis
We collected demographic characteristics, comorbidities, clinical presentation, diagnostic 
work-up including laboratory values, microbiology (including MICs for daptomycin and 
vancomycin when available), and imaging studies, as well as type and duration of antibiotic 
treatment from hospital electronic medical records. The presence of orthopedic hardware at 
the site of infection including prosthesis and internal or external fixation was identified. 
Follow-up laboratory values and imaging studies as well as outcomes, including adverse 
events, were identified through review of outpatient electronic medical records from the 
infectious disease clinic. Mean serum vancomycin trough concentrations encompassing the 
entire treatment period and averaged over all measurements were calculated for all patients 
receiving vancomycin as well as for those pre-treated with vancomycin prior to starting 
daptomycin. For daptomycin, creatine phosphokinase (CPK) levels obtained during therapy 
were reviewed to determine a peak level. Reasons for changing antibiotic therapy (e.g., 
clinical failure, microbiological failure including discovery of VISA, toxicity-related 
discontinuation, or problems stemming from convenience or insurance-related issues) were 
documented. At our institution, a S. aureus strain with an elevated vancomycin MIC of 4 to 
8 mcg/mL is considered VISA.
We compared drug toxicity, medical/surgical management, and clinical outcomes in patients 
treated with daptomycin vs. vancomycin. This comparison was based on the following 
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endpoints: 1) Treatment success, which was defined as resolution of signs and symptoms 
and improvement of function and normalization of inflammatory markers (when available) 
and no repeat surgery for osteomyelitis after discharge and no readmission related to the 
osteomyelitis within 8 weeks (of starting antibiotics); and 2) Tolerability of antibiotic 
treatment including occurrence of and readmission for adverse events and early 
discontinuation of prescribed antibiotic if associated with adverse events. Treatment success 
rates were calculated both with inclusion of those lost to follow-up as failures and excluding 
those lost to follow-up altogether. Clinical outcomes were compared, adjusting for 
propensity to antibiotic assignment using propensity score methods. For this purpose, we 
created a regression model predicting assignment to either study antibiotic. A weighted 
score was assigned to patients in the daptomycin (1/probability) and vancomycin groups 
[1/(1−probability)]. Then, in a logistic regression to elicit predictors of clinical success at six 
months, we included variables that had a p<0.1 in univariate analysis along with the 
weighted propensity score. Adverse events included C. difficile infection, bloodstream 
infection attributed to a central venous catheter, elevated liver function tests, elevated CPK, 
nephrotoxicity (serum creatinine ≥1.5 mg/dL), leukopenia (white blood cell count ≤3.5 cells 
per μL), and a rash and/or allergic reaction.
Statistical analysis was conducted using SPSS version 18 (SPSS Inc., Chicago IL). This 
study was approved by the Washington University Human Research Protection Office.
Results
We identified 20 patients with MRSA OAIs treated with daptomycin and 237 treated with 
vancomycin during the study period. Of the patients treated with vancomycin, forty were 
matched as controls to the twenty daptomycin cases by month and year of hospital 
admission. Overall, the patients’ median age was 52 years (range, 25–90 years), 40 (67%) 
out of 60 were male, and 40 (67%) were white (Table 1). Most patients had osteomyelitis 
(82%) and a contiguous source of infection (87%). Eleven patients (18%) had isolated septic 
arthritis, whereas an overlapping diagnosis between septic arthritis and osteomyelitis was 
encountered in 10/60 (17%). Forty percent of the total study population was diabetic. Eight 
of sixty (13%) patients had renal insufficiency (serum creatinine >1.5 mg/dL) on admission. 
Seven (12%) had peripheral vascular disease.
The mean daptomycin dose encountered in the cases was 6.0 mg/kg (±0.6 mg/kg), in 
accordance with standard dosing of the drug for bloodstream infection. The mean serum 
vancomycin trough concentration achieved in controls receiving only vancomycin was 17.8 
μg/mL, in accordance with recommended target concentrations of 15–20 μg/mL for MRSA 
OAI [3]. In the vancomycin group, there were more diabetic patients compared to the 
daptomycin group [20/40 (50%) vs. 4/20 (20%); p=0.03]. Conversely, in the vancomycin 
group there were fewer patients with preexisting hardware at the site of the infection 
compared to the other group [18/40 (45%) vs. 16/20 (80%); p=0.01]. Approximately half of 
the patients in the daptomycin and vancomycin groups had a prior history of osteoarticular 
infection at the same site [10/20 (50%) vs. 19/40 (48%); p=0.9] suggesting that the current 
infection was either chronic or relapsing; the remainder were acute. Vancomycin was more 
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often part of an antibiotic combination regimen than daptomycin [22 (55%) vs. 5 (25%); 
p=0.03].
The median treatment duration was 39 days for daptomycin (range 3–112) vs. 46 days for 
vancomycin (range 21–135) (p=0.01). However, most patients in the daptomycin group had 
initially been treated with vancomycin (18/20; 90%), receiving a median 14.5 days (range 2–
36) of vancomycin prior to switching to daptomycin. Out of twenty patients in the 
daptomycin group, fourteen (70%) received ≥4 weeks of treatment with daptomycin and 
only two (10%) received ≤1 week. Taking into account pre-treatment with vancomycin, 
median total antibiotic treatment duration was 48 days for the daptomycin group (range 26–
118) vs. 46 days for the vancomycin group (range 21–135) (p=0.5). Patients receiving 
daptomycin underwent more surgeries during the initial hospital admission than patients on 
vancomycin (1.8±0.8 vs. 1.4±0.6; p=0.04).
Treatment success was achieved in 70% (42/60) of all patients at 3 months and in 62% 
(37/60) at 6 months after completing intravenous antibiotics when loss to follow-up was 
considered equivalent to failure. Documented success rates were similar between 
daptomycin and vancomycin at 3 months [15/20 (75%) vs. 27/40 (68%); p=0.8] and 6 
months [14/20 (70%) vs. 23/40 (58%); p=0.5]. When those lost to follow-up were excluded 
from analysis, treatment success in all patients improved to 84% (42/50) at 3 months and 
82% (37/45) at 6 months. Success rates likewise improved for both daptomycin and 
vancomycin at 3 months [15/18 (83%) vs. 27/32 (84%); p=1.0] and 6 months [14/16 (87%) 
vs. 23/29 (79%); p=0.7].
As indicated before, diabetes mellitus predicted assignment to vancomycin in univariate 
analysis. In contrast, the presence of orthopedic hardware predicted assignment to 
daptomycin. Both variables were included in the propensity score for antibiotic assignment. 
Even after adjustment for propensity scores, antibiotic assignment to receive daptomycin or 
vancomycin was not predictive of clinical outcomes at six months [OR 0.55 (95% CI 0.08–
3.74)]. However, the absence of an antibiotic allergy was associated with more favorable 
outcomes when compared to those with a history of antibiotic allergy [21/32 (92%) vs. 8/13 
(62%); p=0.03]; this association persisted in a multivariate model [OR 0.2 (95% CI 0.03–
0.85)].
The frequency of adverse events did not differ significantly between treatment groups [1 
(5%) with daptomycin vs. 7 (18%) with vancomycin; p=0.2], although patients in the 
daptomycin group experienced three-fold fewer adverse events than those receiving 
vancomycin. The single patient with an adverse event reported in the daptomycin group 
experienced a CPK elevation meeting criteria for discontinuation of the drug (CPK >5 times 
the upper limit of normal in the presence of signs of myopathy or CPK ≥10 times the upper 
limit of normal in the absence of symptoms). Six out of seven patients with adverse events 
in the vancomycin group had nephrotoxicity attributed to that antibiotic.
Of the 20 patients in the daptomycin group, 18 (90%) were pre-treated with vancomycin. 
The reasons for replacing vancomycin with daptomycin were rash (including red man’s 
syndrome) (5/20; 25%), failure to achieve therapeutic vancomycin levels (5/20; 25%), 
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detection of a vancomycin-intermediate isolate (4/20; 20%), nephrotoxicity (3/20; 15%), 
leukopenia (2/20; 10%), and clinical failure (2/20; 10%). Patients could have more than one 
reason warranting discontinuation of vancomycin.
Discussion
Daptomycin first became available in 2003 as an option to treat Gram-positive bacteria such 
as Staphylococcus aureus but is not currently FDA-approved for osteoarticular infections. 
Yet, it has been increasingly used to treat OAIs, particularly in the setting of methicillin-
resistant Staphylococcus aureus, and is frequently used as an alternative to vancomycin. 
Little evidence exists to support this practice. In this small nested case-control study with 
comparison of outcomes of patients with MRSA bone and joint infections adjusted for 
propensity to antibiotic assignment, we found that daptomycin and vancomycin achieved 
similar rates of clinical success and drug tolerability. Based on these data, daptomycin is a 
reasonable alternative to vancomycin for treating MRSA bone and joint infections.
Head-to-head clinical trials of different antibiotics for osteoarticular infections are scarce 
[14]. Current practices are therefore driven by lower-quality comparisons or expert opinion. 
For a subset of osteoarticular infections, prosthetic joint infections, the Infectious Diseases 
Society of America (IDSA) has recently issued the first national management guidelines 
[15]. There, daptomycin is mentioned as an alternative treatment option for staphylococcal 
and enterococcal infections. In a separate IDSA guideline on MRSA infections, both 
vancomycin and daptomycin are named as possible agents for treating bone and joint 
infections. While daptomycin has been shown to be equivalent to vancomycin and other 
comparators in a landmark randomized-controlled trial on staphylococcal bloodstream 
infections and endocarditis [16], no such data exist for orthopedic infections. Lalani and 
colleagues used the data from the study mentioned above to conduct a post hoc analysis of 
patients who subsequently developed osteoarticular infections. Their report was limited by 
small numbers (i.e., a total of 11 patients with MRSA osteoarticular infections) [13]. 
Another more recent study by Moenster and colleagues performed at a Veterans Affairs 
hospital compared daptomycin and vancomycin for osteoarticular infections but included 
only a subset of 23 patients with infections caused by MRSA [12]. The authors noted fewer 
recurrences of infection in the daptomycin group, although these findings may have limited 
generalizability to more heterogeneous, non-veteran populations. As in our study, the 
majority of patients eventually treated with daptomycin had initially started on vancomycin; 
reasons leading to changes in antibiotics were not reported. In contrast, our study focused on 
MRSA infections, which in our experience represent the primary indication for using 
daptomycin, and included a larger sample size and a more diverse population than previous 
studies. We also believe that our findings are among the first to demonstrate the wide range 
of reasons for switching from vancomycin to daptomycin in clinical practice. In our 
relatively small study, outcomes were similar across the groups, even after antibiotic 
assignment was adjusted for propensity scores. This is particularly interesting given that 
patients in the daptomycin group were often pre-treated with vancomycin and more complex 
(they were more likely to have hardware-associated infection and required more surgeries). 
While the propensity for assignment to daptomycin vs. vancomycin treatment was not found 
to predict clinical outcomes, a history of antibiotic allergy was predictive of poorer 
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outcomes. A history of antibiotic allergy may be a marker for treatment with second-line 
agents, resulting in a greater likelihood of refractory disease. In fact, some evidence 
indicates that a history of antibiotic allergy impacts patient outcomes [17]. Lastly, more 
diabetic patients were seen in the vancomycin group than those on daptomycin; this may be 
a reflection of the general acceptance of vancomycin as part of a combination regimen for 
diabetic osteoarticular infections. No robust evidence argues against the use of daptomycin 
in diabetic patients [18].
Future studies of comparative effectiveness of daptomycin vs. other antimicrobial agents 
will likely be compromised by the fact that, in our experience, daptomycin is rarely initiated 
as first-line therapy for osteoarticular MRSA infections, supporting the need for randomized 
controlled trials. One major reason for deferring the use of daptomycin is the anticipated 
cost of treatment, which is also influenced by the prolonged treatment duration required to 
achieve cure in bone and joint infections. In the U.S., the average cost of therapy associated 
with daptomycin is more than thirty times that of vancomycin [19]. Among the limitations 
of our study are the relatively small number of cases, which reflects the still relatively 
uncommon use of daptomycin at our institution, and the single-center and retrospective 
design. Follow-up was limited to 6 months after intravenous treatment completion; however, 
some data suggest that most infection recurrences are identified in the first few months after 
treatment, and more extended observation for endpoints may not be necessary [20].
Conclusions
Our findings support daptomycin as a useful and well-tolerated option for treating 
methicillin-resistant Staphylococcus aureus, one of the most common pathogens associated 
with osteoarticular infections. Outcomes of daptomycin-treated infections were similar to 
those treated with vancomycin, even for pre-treated and complex patients and for those who 
had experienced toxicities related to the prior antibiotic.
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Table 1
Comparison of 60 patients with osteoarticular infections due to methicillin-resistant Staphylococcus aureus 
(MRSA), by treatment group
Total n=60 Daptomycin n=20 Vancomycin n=40 p-value
Age (mean ± SD, years) 51.7 (±16.5) 51.5 (±15.9) 51.9 (±16.9) 0.9
Male 40 (67%) 12 (60%) 28 (70%) 0.4
White race 40 (67%) 14 (70%) 26 (65%) 0.3
Body mass index (mean ± SD, kg/cm2) 30.0 (±7.9) 32.2 (±7.4) 29.1 (±8.0) 0.2
Antibiotic allergy (any) 17 (28%) 6 (30%) 11 (27.5%) 0.8
 Penicillin allergy 7 (12%) 1 (5%) 6 (15%) 0.4
Prior osteoarticular infection 29 (48%) 10 (50%) 19 (48%) 0.9
Prior MRSA infection 27 (45%) 10 (50%) 17 (43%) 0.6
Diabetes mellitus 24 (40%) 4 (20%) 20 (50%) 0.03
Rheumatoid arthritis 2 (3%) 1 (5%) 1 (3%) 1.0
Peripheral vascular disease 7 (12%) 0 (0%) 7 (18%) 0.08
Degenerative joint disease 2 (3%) 0 (0%) 2 (5%) 0.5
Renal insufficiency 8 (13%) 1 (5%) 7 (18%) 0.2
Human immunodeficiency virus infection 1 (2%) 0 (0%) 1 (3%) 1.0
Current cancer 2 (3%) 1 (5%) 1 (3%) 1.0
Immunosuppression (steroids, immune-modulators, chemotherapy) 3 (5%) 0 (0%) 3 (8%) 0.5
Current or former smoker 34 (57%) 12 (60%) 22 (55%) 0.7
Orthopedic hardware present on admission 34 (57%) 16 (80%) 18 (45%) 0.01
Osteomyelitis 49 (82%) 16 (80%) 33 (83%) 1.0
Septic arthritis 11 (18%) 4 (20%) 7 (18%) 1.0
Fever on admission (>38.3° Celsius) 9 (15%) 3 (15%) 6 (15%) 1.0
Diagnostics on admission
Blood cultures drawn on admission 31 (52%) 11 (55%) 20 (50%) 0.7
 ≥1 positive blood culture (any organism) 7/31 (23%) 3/11 (27%) 4/20 (20%) 0.7
Radiography consistent with bone or joint infection 27/43 (63%) 10/17 (59%) 17/26 (65%) 0.7
CT scan consistent with bone or joint infection 9/9 (100%) 5/5 (100%) 4/4 (100%) 1.0
MRI consistent with bone 7/7 (100%) N/A 7/7 (100%) N/A
White blood cell count (mean ± SD, cells per μL) 10.6 (±4.5) 9.5 (±4.9) 11.1 (±4.2) 0.2
Serum creatinine (median, range, mg/dL) 0.9 (0.4–5.5) 0.8 (0.4–5.5) 0.9 (0.5–2.2) 0.5
ESR (median, range, mm/h) 63 (1–119) 55 (1–106) 67 (4–119) 0.8
CRP (median, range, mg/dL) 68 (1–352) 90 (2–338) 48 (1–352) 0.2
Study antibiotic given as part of combination antibiotic therapy 27 (45%) 5 (25%) 22 (55%) 0.03
Any surgical treatment 51 (85%) 19 (95%) 32 (80%) 0.2
Outcomes
Evidence of improvement on initial follow-up 57 (95%) 19 (95%) 38 (95%) 1.0
Treatment successful at 3 month follow-up 42/60 (70%) 15/20 (75%) 27/40 (68%) 0.8
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Total n=60 Daptomycin n=20 Vancomycin n=40 p-value
Treatment successful at 6 months follow-up 37/60 (62%) 14/20 (70%) 23/40 (58%) 0.5
NOTE. All values expressed as n (%), unless otherwise noted. SD = standard deviation, CT = computed tomography, MRI = magnetic resonance 
imaging, ESR = erythrocyte sedimentation rate, CRP = C-reactive protein.
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